Cyproterone acetate (CPA) is a progestogen and antiandrogen steroid medication that is used primarily in the treatment of prostate cancer, precocious puberty, acne, and excessive hair growth in women. It acts as a progesterone agonist or antagonist and as an antiandrogen by competing for the androgen receptor. CPA was one of the earliest clinically used antiandrogens and remains an important medication in clinical use today. It is available both as a standalone medication and in combination with an estrogen under various brand names throughout the world.
Market Dynamics:
The global cyproterone acetate market is driven by the increasing incidence of prostate cancer in men, and rising cases of acne and hirsutism in women. Moreover, shifting lifestyle patterns and growing geriatric population are major factors fueling the market growth. However, side effects associated with the long-term use of cyproterone acetate such as liver toxicity, fatigue, and depression along with the availability of alternative medications are expected to hamper market expansion to some extent. The development of conjugated forms of CPA with improved safety profiles can create lucrative opportunities over the forecast period.
Key Features of the Study:
- This report provides in-depth analysis of the global cyproterone acetate market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cyproterone acetate market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Curia, Axplora, LGM Pharma, Hubei Gedian Humanwell Pharmaceutical, Cipla, NEWCHEM SPA, Swati Spentose, Teva API, Teva Pharmaceutical Industries, Unipex, Zhejiang Xianju Pharmaceutical Co. Ltd, KRKA, Cambrex, Sicor De México, Zhejiang Xianju Xianle, Shaoxing Hantai Pharma, and Farmabios
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cyproterone acetate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cyproterone acetate market
Detailed Segmentation:
- Formulation Insights (Revenue, USD Mn, 2019 - 2031)
-
- Tablets
- Injectables
- Topical Preparations
- Application Insights (Revenue, USD Mn, 2019 - 2031)
-
- Hormonal Replacement Therapy
- Contraception
- Acne Treatment
- Others
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Curia
- Axplora
- LGM Pharma
- Hubei Gedian Humanwell Pharmaceutical
- Cipla
- NEWCHEM SPA
- Swati Spentose
- Teva API
- Teva Pharmaceutical Industries
- Unipex
- Zhejiang Xianju Pharmaceutical Co. Ltd
- KRKA
- Cambrex
- Sicor De México
- Zhejiang Xianju Xianle
- Shaoxing Hantai Pharma
- Farmabios
